Long-term maintenance therapy in interferon-α2a/interleukin-2- pretreated advanced renal-cell carcinoma patients

Cancer Biotherapy and Radiopharmaceuticals

Volumn 21, Issue 3, 2006, Pages 206-210

  Atzpodien, Jens ^a,b,c   Reitz, Martina ^c  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c Europaisches Institut fur Tumor Immunologie und Pravention   (Germany)

Author keywords

Immunotherapy; Maintenance; Renal carcinoma; Retinoids

Indexed keywords

ALPHA2 INTERFERON; CAPECITABINE; FLUOROURACIL; INTERLEUKIN 2; ISOTRETINOIN; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADULT; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; IMMUNOTHERAPY; KIDNEY CARCINOMA; LONG TERM CARE; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; SYSTEMIC THERAPY; TREATMENT OUTCOME;

BIOLOGICAL RESPONSE MODIFIERS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INTERFERON ALFA-2A; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MODELS, STATISTICAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 33746374349     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.21.206     Document Type: Article

References (14)

1. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889.
2. Atzpodien J, Korfer A, Franks CR, et al. Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet 1990;335:1509.
3. Sleijfer DT, Janssen RA, Buter J, et al. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal-cell cancer on an outpatient basis. J Clin Oncol 1992;10:1119.
4. Jayson GC, Middleton M, Lee SM, et al. A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer. Br J Cancer 1998;78:366.
5. Tourani JM, Poster C, Tubiana N, et al. Subcutaneous interleukin-2 and interferon-alfa administration in patients with metastatic renal-cell carcinoma: Final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design-the Subcutaneous Administration Propeukin Program Cooperative Group. J Clin Oncol 2003;21(21):3987.
6. Vogelzang NJ, Lipton A, Figlin RA. Subcutaneous interleukin-2 plus Interferon alfa-2a in metastatic renal cancer: An outpatient multicenter trial. J Clin Oncol 1993;11(9):1809.
7. Piga A, Giordana P, Quattrone A, et al. A phase II study of interferon alpha and low-dose subcutaneous interleukin-2 in advanced renal-cell carcinoma. Cancer Immunol Immunother 197;44(6):348.
8. Stadler WM, Kuzel T, Dumas M, et al. Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma. J Clin Oncol 1998;6:1820.
9. Atzpodien J, Kirchner H, Duensing S, et al. Biochemotherapy of advanced metastatic renal-cell carcinoma: Results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cisretinoic acid. World J Urol 1995;13:174.
10. Atzpodien J, Kirchner H, Jonas U, et al. Interleukin-2 and Interferon alfa2a-based immunochemotherapy in advanced renal cell carcinoma: Results of a prospectively randomized trial of The German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 2004;22(7):1188.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Ass 1958;53:457.
12. Atzpodien J, Kirchner H, Rebmann U, et al. Interleukin-2-/interferon- alpha2a-/13-cis-retinoic acid-based chemoimmunotherapy in advanced renal-cell carcinoma: Results of a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCEM). J Clin Oncol submitted, 2006.
13. Aass N, De Mulder PHM, Mickisch GHJ, et al. Randomized phase II/III trial of interferon alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastastic renal cell carcinoma: The European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). J Clin Oncol 2005;23:4172.
14. Motzer RJ, Murphy BA, Bacik J, et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000;18:2972.